Cyclosporine A up-regulates angiotensin II receptors and calcium responses in human vascular smooth muscle cells

Kidney International

Volumn 55, Issue 6, 1999, Pages 2407-2414

  Avdonin, Pavel V ^a,b   Cottet Maire, Florence ^a,b   Afanasjeva, Galina V ^a,b   Loktionova, Svetlana A ^a,b   Lhote, Philippe ^a,b   Ruegg, Urs T ^a,b  

^a KOL TSOV INSTITUTE OF DEVELOPMENTAL BIOLOGY   (Russian Federation)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Ang II; CsA; Cytoplasmic calcium; Hypertension; Nephrotoxicity; Smooth muscle cells; Vasoconstriction

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR; ARGIPRESSIN; CALCINEURIN; CALCIUM; CALCIUM 45; CYCLOSPORIN A; CYCLOSPORIN H; DACTINOMYCIN; ENDOTHELIN 1; FURA 2; THAPSIGARGIN;

ADOLESCENT; ADULT; AORTA; ARTICLE; CALCIUM TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; FLUOROMETRY; HUMAN; HUMAN CELL; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; RECEPTOR BINDING; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

EID: 0033059978     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.00481.x     Document Type: Article

References (44)

1. 1. Cardenas ME, Zhu D, Heitman J: Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin. Curr Opin Nephrol Hypertens 4:472-477, 1995
2. 2. Borel JF, Baumann G, Chapman I, Donatsch P, Fahr A, Mueller EA, Vigouret JM: In vivo pharmacological effects of ciclosporin and some analogues. Adv Pharmacol 35:115-246, 1996
3. 3. Kahan BD: Cyclosporine. N Engl J Med 321:1725-1738, 1989
4. 4. Skorecki KL, Rutledge WP, Schrier RW: Acute cyclosporine nephrotoxicity: Prototype for a renal membrane signaling disorder. Kidney Int 42:1-10, 1992
5. 5. Textor SC, Canzanello VJ, Taler SJ, Wilson DJ, Schwartz LL, Augustine JE, Raymer JM, Romero JC, Wiesner RH, Krom RA, Burnett JC: Cyclosporine-induced hypertension after transplantation. Mayo Clin Proc 69:1182-1193, 1994
6. 6. Xue H, Bukoski RD, McCarron DA, Bennett WM: Induction of contraction in isolated rat aorta by cyclosporine. Transplantation 43:715-718, 1987
7. 7. Lamb FS, Webb RC: Cyclosporine augments reactivity of isolated blood vessels. Life Sci 40:2571-2578, 1987
8. 8. Kaye D, Thompson J, Jennings G, Esler M: Cyclosporine therapy after cardiac transplantation causes hypertension and renal vasoconstriction without sympathetic activation. Circulation 88:1101-1109, 1993
9. 9. Roullet JB, Xue H, McCarron DA, Holcomb S, Bennett WM: Vascular mechanisms of cyclosporin-induced hypertension in the rat. J Clin Invest 93:2244-2250, 1994
10. 10. Ferrario CM: Importance of the renin-angiotensin-aldosterone system (RAS) in the physiology and pathology of hypertension: An overview. Drugs 39(Suppl 2):1-8, 1990
11. 11. Haws RM, Shaul PW, Arant BS Jr, Atiyeh BA, Seikaly MG: Glomerular losartan (DuP 753)-sensitive angiotensin II receptor density is increased in young spontaneously hypertensive rats. Pediatr Res 35:671-676, 1994
12. 12. Wu JN, Edwards D, Berecek KH: Changes in renal angiotensin II receptors in spontaneously hypertensive rats by early treatment with the angiotensin-converting enzyme inhibitor captopril. Hypertension 23(6 Part 2):819-822, 1994
13. 13. Sato A, Suzuki H, Nakazato Y, Shibata H, Inagami T, Saruta T: Increased expression of vascular angiotensin II type 1A receptor gene in glucocorticoid-induced hypertension. J Hypertension 12:511-516, 1994
14. 14. Iwai J, Kanayama Y, Negoro N, Inoue T, Okamura M, Takeda T: Increased gene expression of angiotensin II type 1A receptor in aortic smooth muscle cells of cyclosporin A-induced hypertensive rats. J Hypertens 11(Suppl 5):S122-S123, 1993
15. 15. Pfeilschifter J, Ruegg UT: Cyclosporin A augments angiotensin II-stimulated rise in intracellular free calcium in vascular smooth muscle cells. Biochem J 248:883-887, 1987
16. 16. Lo Russo A, Passaquin AC, André P, Skutella M, Ruegg UT: Effect of cyclosporin A and analogues on cytosolic calcium and vasoconstriction: Possible lack of relationship to immunosuppressive activity. Br J Pharmacol 118:885-892, 1996
17. 17. Orekhov AN, Kosykh VA, Repin VS, Smirnov VN: Cell proliferation in normal and atherosclerotic human aorta. I. Flow cytofluorometric determination of cellular deoxyribonucleic acid content. Lab Invest 48:395-398, 1983
18. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 260:3440-3450, 1985
19. 19. Bradford M: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254, 1976
20. 20. Corriu C, Andre P, Schott C, Michel M, Stoclet JC: ANG II receptor expression and function during phenotypic modulation of rat aortic smooth muscle cells. Am J Physiol 266(2 Part 2):H631-H636, 1994
21. 21. Lo Russo A, Passaquin A-C, Rüegg UT: Mechanism of enhanced vasoconstrictor hormone action in vascular smooth muscle cells by cyclosporin A. Br J Pharmacol 121:248-252, 1997
22. 22. McKeon F: When worlds collide: Immunosuppressants meet protein phosphatases. Cell 66:823-826, 1991
23. 23. Fliri H, Baumann G, Enz A, Kallen J, Luyten M, Mikol V, Movva R, Quesniaux V, Schreier M, Walkinshaw M, Wenger R, Zenke G, Zurini M: Cyclosporins: Structure-activity relationships. Ann NY Acad Sci 696:47-53, 1993
24. 24. Sturrock ND, Lang CC, Struthers AD: Cyclosporin-induced hypertension precedes renal dysfunction and sodium retention in man. J Hypertens 11:1209-1216, 1993
25. 25. Fahr A: Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 24:472-495, 1993
26. 2+ fluxes in isolated hepatocytes. J Biol Chem 260:13613-13618, 1985
27. 27. Rego A, Vargas R, Suarez KR, Foegh ML, Ramwell PW: Mechanism of cyclosporin potentiation of vasoconstriction of the isolated rat mesenteric arterial bed: Role of extracellular calcium. J Pharmacol Exp Ther 254:799-808, 1990
28. 28. Meyer-Lehnert H, Bokemeyer D, Friedrichs U, Backer A, Kramer HJ: Cellular mechanisms of cyclosporine A-associated side-effects: Role of endothelin. Kidney Int 52(Suppl 61):S27-S31, 1997
29. 29. Handschumacher RE, Harding MW, Rice J, Drugge RJ, Speicher DW: Cyclophilin: A specific cytosolic binding protein for cyclosporin A. Science 226:544-547, 1984
30. 30. Goldberg HJ, Wong PY, Cole EH, Levy GA, Skorecki KL: Dissociation between the immunosuppressive activity of cyclosporine derivatives and their effects on intracellular calcium signaling in mesangial cells. Transplantation 47:731-733, 1989
31. 31. Muhl H, Kunz D, Rob P, Pfeilschifter J: Cyclosporin derivatives inhibit interleukin 1-beta induction of nitric oxide synthase in renal cells. Eur J Pharmacol 249:95-100, 1993
32. 32. Ramirez-Bosca A, Kanitakis J, Haftek M, Faure M, Castells-Rodellas A, Thivolet J: Nonimmunosuppressive cyclosporin H inhibits the growth and DNA synthesis of cultured normal human epidermal keratinocytes. Skin Pharmacol 2:175-179, 1989
33. 33. Amsellem C, Haftek M, Kanitakis J, Thivolet J: Effect of cyclosporins A, G, and H on normal and ichthyotic keratinocyte growth in culture. Arch Dermatol Res 284:173-178, 1992
34. 2+/calmodulin dependent EF-2 phosphorylation in vitro. Biochem Biophys Res Commun 150:545-551, 1988
35. 35. Walker RJ, Lazzaro VA, Duggin GG, Horvath JS, Tiller DJ: Structure-activity relationships of cyclosporines: Toxicity in cultured renal tubular epithelial cells. Transplantation 48:321-327, 1989
36. 36. Meyer-Lehnert H, Schrier RW: Potential mechanism of cyclosporine A-induced vascular smooth muscle contraction. Hypertension 13:352-360, 1989
37. 37. Hartmann A, Schweitzer G, Stratmann D, Kaltenbach M, Kober G: Effects of nitrendipine and lisinopril on blood pressure and sodium excretion in cyclosporin-associated hypertension after heart transplantation. Cardiology 83:141-149, 1993
38. 38. Mimran A, Ribstein J: Angiotensin-converting enzyme inhibitors versus calcium antagonists in the progression of renal diseases. Am J Hypertension 7(9 Part 2):73S-81S, 1994
39. 2+ in the cytoplasm of thrombocytes in hypertensive patients. Kardiologiia 28:72-77, 1988
40. 40. Orlov SN, Pokudin NI, Postnov IV: Intracellular concentration of free calcium in thrombocytes: Its characteristics in spontaneous hypertension. Kardiologiia 24:93-98, 1984
41. 41. Cortes SF, Lemos VS, Corriu C, Stoclet JC: Changes in angiotensin II receptor density and calcium handling during proliferation in SHR aortic myocytes. Am J Physiol 271(6 Part 2):H2330-H2338, 1996
42. 42. Song K, Kurobe Y, Kanehara H, Wada T, Inada Y, Nishikawa K, Miyazaki M: Mapping of angiotensin II receptor subtypes in peripheral tissues of spontaneously hypertensive rats by in vitro autoradiography. Clin Exp Pharmacol Physiol (Suppl 1):S17-S19, 1995
43. 43. Brown L, Sernia C: Angiotensin receptors in cardiovascular diseases. Clin Exp Pharmacol Physiol 21:811-818, 1994
44. 44. Luke RG: Essential hypertension: A renal disease? A review and update of the evidence. Hypertension 21:380-390, 1993